Can Coffee Protect Against Alzheimer’s and Parkinson’s Disease?

MedicalResearch.com Interview with:
"coffee cappuccino art maple leaf via quattrone" by skeddy in NYC is licensed under CC BY 2.0Donald Weaver, PhD, MD, FRCPC, FCAHS
Senior Scientist and Director, Research Institute
Krembil Research Institute
University Health Network
Toronto, Canada

MedicalResearch.com: What is the background for this study? What are the main findings?

Response: First, we are seeking novel molecules that might have usefulness in the treatment of Alzheimer’s disease (AD).  Since Mother Nature is a superb chemist, natural products are an ideal place to start looking for possible therapeutics.  There is a long history (penicillin, digitalis …) of drugs identified from natural product sources.  Moreover, in earlier work by us, we have shown that other natural products extracted from maple syrup have possible therapeutic efficacy against AD.

Therefore, it was logical for us to look at extracts of coffee.  We see similarities between maple syrup and coffee.  In both of these natural products, the plant derived material (i.e. the coffee bean, or sap from maple syrup) is initially boiled or roasted prior to its use; thus, it is not a direct simple plant product, but one that has been heated (boiled or roasted).  We suspect that the heating process “does more chemistry” enabling the generation of new molecules from the plant derived materials.  In our study we show that a class of compounds (phenylindanes) from roasted coffee has the ability to inhibit the misfolding of two proteins (beta-amyloid, tau) whose misfolding and aggregation (“clumping”) is implicated in the disease process of AD.

Second, as described below, there is already epidemiological evidence that coffee consumption may offer some protective effects against Alzheimer’s disease  and Parkinson’s disease (PD), so by looking at the constituents of coffee for chemicals that might block the clumping of beta-amyloid and/or tau, was an attempt to seek a molecular link explaining the epidemiology.   

MedicalResearch.com How does this study build on the current epidemiological evidence about the link between coffee and Alzheimer’s disease?

Response: Epidemiological evidence suggests that coffee consumption may offer some protection against the development of Alzheimer’s disease  and Parkinson’s disease. Alzheimer’s disease and PD are both neurodegenerative diseases, which share a similarity.  The similarity is that they are both regarded as protein misfolding diseases.  In AD, the two proteins that misfold are beta-amyloid and tau; in PD the protein that misfolding is alpha-synuclein.  Accordingly, we sought to connect the epidemiological observation that coffee is protective, by examining the chemical components of coffee for chemical(s) that prevent protein misfolding.  As mentioned above, we identified phenylindanes as agents which prevent the misfolding and clumping of beta-amyloid and tau.  Therefore, there is a possibility that natural products such as phenylindanes are the explanatory link explaining the epidemiologically identified relationship between coffee consumption and AD/PD.  However, this is only a suggestion.  More work (see next question) is required before one can categorically state that this is indeed the explanation.  

MedicalResearch.com: What recommendations do you have for future research as a result of this work?

Response: This is just a start.  Are phenylindanes the ingredient in coffee that explains coffee’s protective effect?  Too early to say! There is much that needs to be studied.  Can phenylindanes actually get into the brain when swallowed in a cup of coffee?  That question remains unanswered.  If they don’t have the ability to cross the blood-brain barrier (BBB) and get into brain, then clearly they are not the explanation.  Also, could phenylindanes alone be the answer? Or, is it really a mixture of multiple chemicals within coffee that exerts the therapeutic effect?  This requires further study.

MedicalResearch.com: How significant is it for potential future therapies, that the compound identified is natural vs. synthetic?  

Response: All drugs are molecules, but not all molecules are drugs.  Natural products have the interesting advantage that they sometimes exhibit structural complexities that Mother Nature is capable of making, but which would be rather challenging and expensive for a chemist to make in a laboratory. On the other hand, many of these natural products are so complex that these interesting structural features actually precludes them from crossing the BBB and entering the brain.  Overall, we don’t think that the phenylindane extract will be a drug, but it might be an interesting and powerful starting point in the design and development of future drugs.

MedicalResearch.com: What should readers take away from your report?

Response: Alzheimer’s disease is an impending pandemic.  As the world’s population increases, the socioeconomic impact of Alzheimer’s Disease will be truly immense and will have grave consequences on our health care systems.  We desperately need a disease modifying drug for AD.  Currently there are NO disease modifying agents for AD.  The drugs which are available are merely “symptomatic” agents of limited usefulness, which really do not alter the natural history of the disease and which are definitely not curative.  We must leave no stone unturned in our quest to find a cure for AD.  Given the long history of therapeutics emerging from natural product sources, studying agents derived from coffee is a reasonable avenue to pursue.

Disclosures: D. Weaver is co-founder and Chief Medical Officer of Treventis Corp.  Treventis is focused on the design and development of new chemical entities as putative therapies for AD.  The work on coffee is not associated with the research activities of Treventis Corp.  The coffee study was an unfunded academic study not associated with any corporate sponsor.    

Citation:

Ross S. Mancini, Yanfei Wang, Donald F. Weaver. Phenylindanes in Brewed Coffee Inhibit Amyloid-Beta and Tau Aggregation. Frontiers in Neuroscience, 2018; 12 DOI: 10.3389/fnins.2018.00735

Nov 14, 2018 @ 12:58 am

The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.

 

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.